These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1051 related items for PubMed ID: 28829153

  • 1. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR, Miller RA, Miller T, Deavers M, Gorman B, Mody D, Ge Y, Barrios R, Bernicker E, Kim M, Cagle PT.
    Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
    [Abstract] [Full Text] [Related]

  • 2. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ, Kim HR, Lee CY, Cho BC, Shim HS.
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
    Del C Monroig-Bosque P, Driver B, Morales-Rosado JA, Deavers M, Tacha D, Bernicker E, Cagle PT, Miller RA.
    Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE, Abdelrahman AE, Abdelgawad M, Balata S, Shabrawy ME.
    Turk Patoloji Derg; 2017 Nov; 1(1):211-222. PubMed ID: 28832075
    [Abstract] [Full Text] [Related]

  • 8. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
    Teramoto K, Igarashi T, Kataoka Y, Ishida M, Hanaoka J, Sumimoto H, Daigo Y.
    Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.
    Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K, Mouroux J, Vénissac N, Poudenx M, Otto J, Sabourin JC, Marquette CH, Hofman V, Hofman P.
    Ann Oncol; 2016 Jan; 27(1):147-53. PubMed ID: 26483045
    [Abstract] [Full Text] [Related]

  • 11. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples.
    Casadevall D, Clavé S, Taus Á, Hardy-Werbin M, Rocha P, Lorenzo M, Menéndez S, Salido M, Albanell J, Pijuan L, Arriola E.
    Clin Lung Cancer; 2017 Nov; 18(6):682-691.e5. PubMed ID: 28549836
    [Abstract] [Full Text] [Related]

  • 12. Clinicopathological characteristics and tumor infiltrating immune cells associations of PD-L1 tumor expression in non-small cell lung cancer patients.
    Aazzane O, Bakhtaoui FZ, Stitou S, Fellah H, Karkouri M.
    Tunis Med; 2024 Apr 05; 102(4):223-228. PubMed ID: 38746962
    [Abstract] [Full Text] [Related]

  • 13. 18F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer.
    Hu B, Chen W, Zhang Y, Shi H, Cheng D, Xiu Y.
    Ann Nucl Med; 2020 May 05; 34(5):322-328. PubMed ID: 32130663
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer.
    Okuma Y, Hishima T, Kashima J, Homma S.
    Cancer Immunol Immunother; 2018 Mar 05; 67(3):495-505. PubMed ID: 29243049
    [Abstract] [Full Text] [Related]

  • 17. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
    Toki MI, Mani N, Smithy JW, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Schalper K, Syrigos KN, Rimm DL.
    J Thorac Oncol; 2018 Dec 05; 13(12):1884-1896. PubMed ID: 30267840
    [Abstract] [Full Text] [Related]

  • 18. Programmed Death-Ligand 1 Expression in Non-Small Cell Lung Carcinoma Biopsies and Its Association with Tumor Infi ltrat ing Lymphocytes and the Degree of Desmoplasia.
    Tancoš V, Grendár M, Farkašová A, Huťka Z, Kviatkovská Z, Plank L.
    Klin Onkol; 2020 Dec 05; 33(1):55-65. PubMed ID: 32075390
    [Abstract] [Full Text] [Related]

  • 19. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM, Helal DS, Sabry NM, Abo El-Nasr M.
    J Egypt Natl Canc Inst; 2018 Dec 05; 30(4):125-131. PubMed ID: 30337185
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.